Medical aspects of bio-terrorism

Toxicon

Volumn 69, Issue , 2013, Pages 131-142

  Balali Mood, Mahdi ^a   Moshiri, Mohammad ^b   Etemad, Leila ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Biological warfare agent; Bioterrorism; Biotoxin

Indexed keywords

ABRIN; AMINOGLYCOSIDE; ANTHRAX VACCINE; ANTIDOTE; BOTULINUM ANTISERUM; BOTULINUM TOXOID; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; CLOSTRIDIUM TOXIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; GLUCOCORTICOID; MYCOTOXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RICIN; RIFAMPICIN; SAXITOXIN; STAPHYLOCOCCUS ENTEROTOXIN B; STREPTOMYCIN; TETRACYCLINE; TOXIN; TOXOID; TRICHOTHECENE; TULAREMIA VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VANCOMYCIN; BIOLOGICAL WARFARE AGENT; CHEMICAL WARFARE AGENT; ANTIBIOTIC AGENT; BACTERIAL TOXIN; EPSILON TOXIN; HYDROXYCHLOROQUINE; LEVOFLOXACIN; OFLOXACIN; PLAGUE VACCINE; PYROGENIC TOXIN; TETRACYCLINE DERIVATIVE; TRICHOTHECENE DERIVATIVE;

ADD ON THERAPY; ANTHRAX; ARTICLE; AWARENESS; BACTERIAL MENINGITIS; BACTERIUM; BIOENGINEERING; BIOLOGICAL WARFARE; BIOLOGICAL WARFARE AGENT; BOTULISM; CLASSIFICATION; CLINICAL FEATURE; DISEASE SEVERITY; EDEMA; ENCEPHALITIS VIRUS; FEVER; FLACCID PARALYSIS; FUNGUS; HANTAVIRUS; HEALTH HAZARD; HEMORRHAGIC FEVER; HUMAN; HYPOTENSION; IMMUNIZATION; INCUBATION TIME; INTOXICATION; MICROORGANISM; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MULTIPLE ORGAN FAILURE; NIPAH VIRUS; NONHUMAN; PLAGUE; PRIORITY JOURNAL; Q FEVER; RICKETTSIA; SMALLPOX; SYMPTOM; TOXIC SHOCK SYNDROME; TULAREMIA; VIRUS; YELLOW FEVER; HEMORRHAGIC FEVERS, VIRAL; METABOLISM; PREVENTION AND CONTROL; PROCEDURES; RISK FACTOR; TICK BORNE ENCEPHALITIS VIRUS; TOXICITY; TUBERCULOSIS, MULTIDRUG-RESISTANT; VACCINATION; METHODOLOGY; TICK BORNE ENCEPHALITIS FLAVIVIRUS; VIRUS HEMORRHAGIC FEVER; BACTERIAL INFECTION; CLOSTRIDIUM PERFRINGENS; CRANIAL NEUROPATHY; DEATH; DIFFERENTIAL DIAGNOSIS; ENVIRONMENTAL FACTOR; EYE IRRITATION; GENETIC ENGINEERING; HYPERTHERMIA; MUCOSA; MULTIDRUG RESISTANCE; SKIN IRRITATION; TICK BORNE ENCEPHALITIS; TUBERCULOSIS;

ANIMALIA; BACTERIA (MICROORGANISMS); CLOSTRIDIUM PERFRINGENS; FUNGI; NIPAH VIRUS; RICKETTSIACEAE; TICK-BORNE ENCEPHALITIS VIRUS GROUP; VARIOLA VIRUS;

ANTHRAX; BIOLOGICAL WARFARE AGENTS; BIOTERRORISM; BOTULISM; CHEMICAL WARFARE AGENTS; ENCEPHALITIS VIRUSES, TICK-BORNE; HEMORRHAGIC FEVERS, VIRAL; HUMANS; PLAGUE; RISK FACTORS; SMALLPOX; TOXINS, BIOLOGICAL; TUBERCULOSIS, MULTIDRUG-RESISTANT; TULAREMIA; VACCINATION;

EID: 84878477148     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2013.01.005     Document Type: Article

References (140)

1. Afshari R., Shafiei S., Sayyahjezhad M., Dadras-Moghaddam D., Balali-Mood M. A botulism outbreak following a wedding in a rural area in northeast Iran. Clin. Toxicol. (Phila) 2007, 45:388.
2. Al-Agamy M.H.M. Tools of biological warfare. Res. J. Microbiol. 2011, 6:193-245.
3. Anderson P.D. Bioterrorism: toxins as weapons. J. Pharm. Pract. 2012, 25:121-129.
4. Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Fine A.D., Hauer J., Layton M., Lillibridge S., Osterholm M.T., O'Toole T., Parker G., Perl T.M., Russell P.K., Swerdlow D.L., Tonat K. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285:1059-1070.
5. Audi J., Belson M., Patel M., Schier J., Osterloh J. Ricin poisoning: a comprehensive review. JAMA 2005, 294:2342-2351.
6. Balali-Mood M., Balali-Mood K., Hosseini Shirazi F. Recent advances in treatment of acute organophosphorous nerve agents poisoning. IJPR 2006, 5:79-87.
7. Balali Mood M., Balali Mood B., Moshiri M. Sulfur mustard. Encyclopedia of Toxicology 2013, Elsevier. third ed. P. Wexler, H. Greim, V. Moser, T.J. Wiegand, J.V.T. Lafarga, A. Peyster, S. Harper, M. Abdollahi, S.C. Gad, S.D. Ray (Eds.).
8. Bartfield J.M., Ushkow B.S., Rosen J.M., Dylong K. Single breath counting in the assessment of pulmonary function. Ann. Emerg. Med. 1994, 24:256-259.
9. Bokori-Brown M., Savva C.G., Fernandes da Costa S.P., Naylor C.E., Basak A.K., Titball R.W. Molecular basis of toxicity of Clostridium perfringens epsilon toxin. Febs J. 2011, 278:4589-4601.
10. Bossi P., Bricaire F. The plague, possible bioterrorist act. Presse Med. 2003, 32:804-807.
11. Bossi P., Tegnell A., Baka A., van Loock F., Hendriks J., Werner A., Maidhof H., Gouvras G. Bichat guidelines for the clinical management of botulism and bioterrorism-related botulism. Euro Surveill. 2004, 9:E13-E14.
12. Bossi P., Tegnell A., Baka A., Van Loock F., Hendriks J., Werner A., Maidhof H., Gouvras G. Bichat guidelines for the clinical management of plague and bioterrorism-related plague. Euro Surveill. 2004, 9:E5-E6.
13. Bossi P., Tegnell A., Baka A., Van Loock F., Hendriks J., Werner A., Maidhof H., Gouvras G. Bichat guidelines for the clinical management of Q fever and bioterrorism-related Q fever. Euro Surveill. 2004, 9:E19-E20.
14. Brinkworth C.S. Identification oRicin in crude and purified extracts from castor beans using on-target tryptic digestion and MALDI mass spectrometry. Anal. Chem. 2010, 82:5246-5252.
15. CDC Q Fever, Symptoms, Diagnosis, and Treatment 2011, Centers for Disease Control and Prevention(CDC). CDC (Ed.).
16. CDC Emergency Preparedness and Response, Bioterrorism Agents/Diseases 2012, Centers for Disease Control and Prevention(CDC).
17. CDC Plague 2012, 6/2012 ed., Centers for Disease Control and Prevention.
18. Centers for Disease Control and Prevention (CDC) Emergency Preparedness and Response, Bioterrorism Agents/Diseases 2012, Centers for Disease Control and Prevention(CDC).
19. Cobbs C.G., Chansolme D.H. Plague. Dermatol. Clin. 2004, 22. 303-312, vi.
20. Cosgrove S.E., Perl T.M., Song X., Sisson S.D. Ability of physicians to diagnose and manage illness due to category a bioterrorism agents. Arch. Intern. Med. 2005, 165:2002-2006.
21. Cowan F.M., Shih T.M., Lenz D.E., Madsen J.M., Broomfield C.A. Hypothesis for synergistic toxicity of organophosphorus poisoning-induced cholinergic crisis and anaphylactoid reactions. J. Appl. Toxicol. 1996, 16:25-33.
22. Croddy E.R., Wirtz J.J., Larsen J. Weapons of Mass Destruction: an Encyclopedia of Worldwide Policy, Technology, and History; Volume I: Chemical and Biological Weapons 2004, ABC-CLIO American Library Association, Santa Barbara california.
23. Crompton R., Gall D. Georgi Markov-death in a pellet. Med. Leg. J. 1980, 48:51-62.
24. Cronquist S.D. Tularemia: the disease and the weapon. Dermatol. Clin. 2004, 22. 313-320, vi-vii.
25. Cutler S.J., Paiba G.A., Howells J., Morgan K.L. Q fever-a forgotten disease?. Lancet Infect. Dis. 2002, 2:717-718.
26. Dakovic A., Sekulic Ž., Rottinghaus G.E., Stojanovic A., Ilicevic S., Kragovic M. T-2 toxin adsorption by hectorite. J. Serb. Chem. Soc. 2009, 74:1283-1292.
27. Darling R.G., Catlett C.L., Huebner K.D., Jarrett D.G. Threats in bioterrorism. I: CDC category A agents. Emerg. Med. Clin. North. Am. 2002, 20:273-309.
28. Dart R.C., Goldfrank L.R., Chyka P.A., Lotzer D., Woolf A.D., McNally J., Snodgrass W.R., Olson K.R., Scharman E., Geller R.J., Spyker D., Kraft M., Lipsy R. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. Ann. Emerg. Med. 2000, 36:126-132.
29. Davidson T.M., Schafer S.F. Rattlesnake bites. Guidelines for aggressive treatment. Postgrad. Med. 1994, 96:107-114.
30. Daya M., Nakamura Y. Pulmonary disease from biological agents: anthrax, plague, Q fever, and tularemia. Crit. Care Clin. 2005, 21. 747-763, vii.
31. de Rezende N.A., Torres F.M., Dias M.B., Campolina D., Chavez-Olortegui C., Amaral C.F. South American rattlesnake bite (Crotalus durissus SP) without envenoming: insights on diagnosis and treatment. Toxicon 1998, 36:2029-2032.
32. Dembek Z.F., Smith L.A., Rusnak J.M. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med. Public Health Prep. 2007, 1:122-134.
33. Dembek Z.F., Smith L.A., Rusnak J.M. Chapter 16 Botulium Toxin. Medical Aspects of Biological Warfare 2008, 1-20. Borden Institute, Office of the Surgeon General, AMEDD Center & School, US Army, Washington D.C. M.K. Lenhart (Ed.).
34. Desjardins A.E. From yellow rain to green wheat: 25 years of trichothecene bisosynthesis research. J. Agric. Food Chem. 2009, 57:4478-4484.
35. Dhaked R.K., Singh M.K., Singh P., Gupta P. Botulinum toxin: bioweapon & magic drug. Indian J. Med. Res. 2010, 132:489-503.
36. Doan L.G. Ricin: mechanism of toxicity, clinical manifestations, and vaccine development. A review. J. Toxicol. Clin. Toxicol. 2004, 42:201-208.
37. Dutta T.K., Sujatha S., Sahoo R.K. Anthrax-update on diagnosis and management. J. Assoc. Physicians India 2011, 59:573-578.
38. Eiros Bouza J.M., Bachiller Luque M.R., Ortiz de Lejarazu R. Guidelines for clinical management of bioterrorism bacterial diseases: anthrax, plague, turalemia and brucellosis. Ann. Med. Interna 2003, 20:540-547.
39. Etzel R.A. Mycotoxins. JAMA 2002, 287:425-427.
40. Fernandez Miyakawa M.E., Uzal F.A. The early effects of Clostridium perfringens type D epsilon toxin in ligated intestinal loops of goats and sheep. Vet. Res. Commun. 2003, 27:231-241.
41. Fodstad O., Olsnes S., Pihl A. Toxicity, distribution and elimination of the cancerostatic lectins abrin and ricin after parenteral injection into mice. Br. J. Cancer 1976, 34:418-425.
42. Franz D. Defense Against Toxin Weapons 1997, U.S. Army Medical Research, Maryland.
43. Frazier A.A., Franks T.J., Galvin J.R. Inhalational anthrax. J. Thorac. Imaging 2006, 21:252-258.
44. Fricke R.F., Jorge J. Methylthiazolidine-4-carboxylate for treatment of acute T-2 toxin exposure. J. Appl. Toxicol. 1991, 11:135-140.
45. Garber E.A. Toxicity and detection of ricin and abrin in beverages. J. Food Prot. 2008, 71:1875-1883.
46. Grandoni K.M., Gentry P.A., Holub B.J., Yagen B. Trichothecene mycotoxins inhibit phosphoinositide hydrolysis in bovine platelets stimulated with platelet activating factor. Toxicology 1992, 72:51-60.
47. Greenfield R.A., Brown B.R., Hutchins J.B., Iandolo J.J., Jackson R., Slater L.N., Bronze M.S. Microbiological, biological, and chemical weapons of warfare and terrorism. Am. J. Med. Sci. 2002, 323:326-340.
48. Greenfield R.A., Drevets D.A., Machado L.J., Voskuhl G.W., Cornea P., Bronze M.S. Bacterial pathogens as biological weapons and agents of bioterrorism. Am. J. Med. Sci. 2002, 323:299-315.
49. Griffiths G.D., Phillips G.J., Holley J. Inhalation toxicology of ricin preparations: animal models, prophylactic and therapeutic approaches to protection. Inhal Toxicol. 2007, 19:873-887.
50. Gustin J.F. Bioterrorism: A Guide for Facility Managers 2005, CRC Press; The Fairmont Press, USA.
51. Henghold W.B. Other biologic toxin bioweapons: ricin, staphylococcal enterotoxin B, and trichothecene mycotoxins. Dermatol. Clin. 2004, 22. 257-262, v.
52. Hepburn M.J., Friedlander R.M., Dembek Z.F. Chapter 8 tularemia. Medical Aspects of Biological Warfare 2008, 167-184. Borden Institute, Office of the Surgeon General, AMEDD Center & School, US Army, Washington D.C. M.K. Lenhart (Ed.).
53. Heyndrickx A., Sookvanichsilp N., Van den Heede M. Detection of trichothecene mycotoxins (yellow rain) in blood, urine and feces of Iranian soldiers treated as victims of a gas attack. Arch. Belg Suppl. 1984, 143-146.
54. Holzer E. Botulism caused by inhalation. Med. Klin 1962, 57:1735-1738.
55. Horowitz B.Z. Botulinum toxin. Crit. Care Clin. 2005, 21. 825-839, viii.
56. Hoskovcova M., Halamek E., Kobliha Z. Study of efficacy of reactivator HI 6 in reactivation of immobilized acetylcholinesterase, inhibited by organophosphorus chemical warfare agents of the " G" series. Drug Metab. Lett. 2009, 3:54-57.
57. Inglesby T.V., Dennis D.T., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Fine A.D., Friedlander A.M., Hauer J., Koerner J.F., Layton M., McDade J., Osterholm M.T., O'Toole T., Parker G., Perl T.M., Russell P.K., Schoch-Spana M., Tonat K. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. Jama 2000, 283:2281-2290.
58. Ishoj T., Jensen K. Chemical warfare poisoning in time of peace. Ugeskr Laeger 1999, 161:808-810.
59. Jernigan D.B., Raghunathan P.L., Bell B.P., Brechner R., Bresnitz E.A., Butler J.C., Cetron M., Cohen M., Doyle T., Fischer M., Greene C., Griffith K.S., Guarner J., Hadler J.L., Hayslett J.A., Meyer R., Petersen L.R., Phillips M., Pinner R., Popovic T., Quinn C.P., Reefhuis J., Reissman D., Rosenstein N., Schuchat A., Shieh W.J., Siegal L., Swerdlow D.L., Tenover F.C., Traeger M., Ward J.W., Weisfuse I., Wiersma S., Yeskey K., Zaki S., Ashford D.A., Perkins B.A., Ostroff S., Hughes J., Fleming D., Koplan J.P., Gerberding J.L. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg. Infect. Dis. 2002, 8:1019-1028.
60. Jernigan J.A., Stephens D.S., Ashford D.A., Omenaca C., Topiel M.S., Galbraith M., Tapper M., Fisk T.L., Zaki S., Popovic T., Meyer R.F., Quinn C.P., Harper S.A., Fridkin S.K., Sejvar J.J., Shepard C.W., McConnell M., Guarner J., Shieh W.J., Malecki J.M., Gerberding J.L., Hughes J.M., Perkins B.A. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg. Infect. Dis. 2001, 7:933-944.
61. Josko D. Botulin toxin: a weapon in terrorism. Clin. Lab. Sci. 2004, 17:30-34.
62. Kagawa F.T., Wehner J.H., Mohindra V. Q fever as a biological weapon. Semin. Respir. Infect. 2003, 18:183-195.
63. Kazar J. Coxiella burnetii infection. Ann. N. Y. Acad. Sci. 2005, 1063:105-114.
64. Keshavarz S.A., Memarbashi A., Balali M. Preventive effect of selenium on T-2 toxin membrane toxicity. Adv. Exp. Med. Biol. 2001, 500:463-466.
65. Ketai L., Tchoyoson Lim C.C. Radiology of biological weapons-old and the new?. Semin. Roentgenol. 2007, 42:49-59.
66. Khardori N. Bioterrorism and bioterrorism preparedness. Infect. Dis. Clin. North. Am. 2006, 20. xiii-xv.
67. Khardori N. Bioterrorism and bioterrorism preparedness: historical perspective and overview. Infect. Dis. Clin. North. Am. 2006, 20. 179-211, vii.
68. Khardori N. Potential agents of bioterrorism: historical perspective and an overview. Bioterrorism Preparedness Medicine - Public Health - Policy 2006, 1-33. WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, Mçrlenbach, Germany. N. Khardori (Ed.).
69. Kianifar H., Balali-Mood M., Kianifar V. Poisoning by T-2 Toxin and its Toxicological Findings, Second Iranian Congress of Poisoning Oct 12-14, 1991, University of Medical Sciences of Tabriz, IRAN.
70. Kirby J.E. Anthrax lethal toxin induces human endothelial cell apoptosis. Infect. Immun. 2004, 72:430-439.
71. Kman N.E., Nelson R.N. Infectious agents of bioterrorism: a review for emergency physicians. Emerg. Med. Clin. North. Am. 2008, 26:517-547.
72. Koshinsky H., Honour S., Khachatourians G. T-2 toxin inhibits mitochondrial function in yeast. Biochem. Biophys. Res. Commun. 1988, 151:809-814.
73. Kravchenko L.V., Kranauskas A.E., Dzhaparidze L.M., Avren'eva L.I., Spirichev V.B. Effect of different supplies of vitamin E on biochemical changes in T-2 mycotoxicosis in rats. Vopr Med Khim 1986, 32:99-103.
74. Krishna G., Chitkara R.K. Pneumonic plague. Semin. Respir. Infect. 2003, 18:159-167.
75. Krysa-Clark J., Lewis S., Waterworth T.A. Management of a snake bite in the field. J. R Army Med. Corps 2004, 150:97-98.
76. Kyriacou D.N., Adamski A., Khardori N. Anthrax: from antiquity and obscurity to a front-runner in bioterrorism. Infect. Dis. Clin. North. Am. 2006, 20. 227-251, viii.
77. Leatherman D.L., Middlebrook J.L. Effect of emetine on T-2 toxin-induced inhibition of protein synthesis in mammalian cells. J. Pharmacol. Exp. Ther. 1993, 266:741-748.
78. Lockwood J.A. Insects as weapons of war, terror, and torture. Annu. Rev. Entomol. 2012, 57:205-227.
79. LoRusso P.M., Lomen P.L., Redman B.G., Poplin E., Bander J.J., Valdivieso M. Phase I study of monoclonal antibody-ricin A chain immunoconjugate Xomazyme-791 in patients with metastatic colon cancer. Am. J. Clin. Oncol. 1995, 18:307-312.
80. Love, A.H., Bailey, C.G., Hanna, M.L., Hok, S., Vu, A.K., Reutter, D.J., Raber, E. Efficacy of liquid and foam decontamination technologies for chemical warfare agents on indoor surfaces. J. Hazard. Mater. 196, 115-122.
81. Lumor S.E., Hutt A., Ronningen I., Diez-Gonzalez F., Labuza T.P. Validation of immunodetection (ELISA) of ricin using a biological activity assay. J. Food Sci. 2011, 76:C112-C116.
82. Lutsky, Mor N. Alimentary toxic aleukia (septic angina, endemic panmyelotoxicosis, alimentary hemorrhagic aleukia): t-2 toxin-induced intoxication of cats. Am. J. Pathol. 1981, 104:189-191.
83. Lutsky I., Mor N. Experimental alimentary toxic aleukia in cats. Lab. Anim. Sci. 1981, 31:43-47.
84. Lutwick L.I., Nierengarten M.B. Vaccines for Category A bioterrorism diseases. Expert Opin. Biol. Ther. 2002, 2:883-893.
85. Madariaga M.G., Rezai K., Trenholme G.M., Weinstein R.A. Q fever: a biological weapon in your backyard. Lancet Infect. Dis. 2003, 3:709-721.
86. Mantis N.J. Vaccines against the category B toxins: staphylococcal enterotoxin B, epsilon toxin and ricin. Adv. Drug Deliv. Rev. 2005, 57:1424-1439.
87. Markham R.J., Erhardt N.P., DiNinno V.L., Penman D., Bhatti A.R. Flavonoids protect against T-2 mycotoxins both in vitro and in vivo. J. Gen. Microbiol. 1987, 133:1589-1592.
88. Marks J.D. Medical aspects of biologic toxins. Anesthesiol. Clin. North. America 2004, 22. 509-532, vii.
89. Mattix M.E., Hunt R.E., Wilhelmsen C.L., Johnson A.J., Baze W.B. Aerosolized staphylococcal enterotoxin B-induced pulmonary lesions in rhesus monkeys (Macaca mulatta). Toxicol. Pathol. 1995, 23:262-268.
90. Mayer T.A., Morrison A., Bersoff-Matcha S., Druckenbrod G., Murphy C., Howell J., Hanfling D., Cates R., Pauze D., Earls J. Inhalational anthrax due to bioterrorism: would current Centers for Disease Control and Prevention guidelines have identified the 11 patients with inhalational anthrax from October through November 2001?. Clin. Infect. Dis. 2003, 36:1275-1283.
91. McQuiston J.H., Childs J.E., Thompson H.A. Q fever. J. Am. Vet. Med. Assoc. 2002, 221:796-799.
92. Middlerook J.L., Franz D.R. Chapter 33, botulinum toxins. Textbook of Military Medicine. Part I. Warfare, Weaponry, and the Casualty. Medical Aspects of Chemical and Biological Warfare 1997, 643-654. Borden Institute, Walter Reed Medical Center, Washington, DC. R. Zajtchuk, R.F. Bellamy, F.R. Sidell (Eds.).
93. Moran G.J. Threats in bioterrorism. II: CDC category B and C agents. Emerg. Med. Clin. North. Am. 2002, 20:311-330.
94. Nigrovic L.E., Wingerter S.L. Tularemia. Infect. Dis. Clin. North. Am. 2008, 22. 489-504, ix.
95. Nowicke J.W., Meselson M. Yellow rain-a palynological analysis. Nature 1984, 309:205-206.
96. Olsnes S. The history of ricin, abrin and related toxins. Toxicon 2004, 44:361-370.
97. Oyston P.C., Davies C. Q fever: the neglected biothreat agent. J. Med. Microbiol. 2011, 60:9-21.
98. Pace J.G., Watts M.R., Canterbury W.J. T-2 mycotoxin inhibits mitochondrial protein synthesis. Toxicon 1988, 26:77-85.
99. Papaloucas M., Papaloucas C., Stergioulas A. Ricin and the assassination of Georgi Markov. Pak J. Biol. Sci. 2008, 11:2370-2371.
100. Paterson R.R. Fungi and fungal toxins as weapons. Mycol. Res. 2006, 110:1003-1010.
101. Patocka J., Splino M., Merka V. Botulism and bioterrorism: how serious is this problem?. Acta Med. (Hradec Kralove) 2005, 48:23-28.
102. Persell D.J., Arangie P., Young C., Stokes E.N., Payne W.C., Skorga P., Gilbert-Palmer D. Preparing for bioterrorism: category A agents. Nurse Pract. 2001, 26. 12-15, 19-24, 27; quiz 28-19.
103. Pinchuk I.V., Beswick E.J., Reyes V.E. Staphylococcal enterotoxins. Toxins (Basel) 2010, 2:2177-2197.
104. Pinson-Gadais L., Richard-Forget F., Frasse P., Barreau C., Cahagnier B., Richard-Molard D., Bakan B. Magnesium represses trichothecene biosynthesis and modulates Tri5, Tri6, and Tri12 genes expression in Fusarium graminearum. Mycopathologia 2008, 165:51-59.
105. Purcell B.K., Worsham P.L., Friedlander R.M. Chapter 4 anthrax. Medical Aspects of Biological Warfare 2008, 65-90. Borden Institute, Office of the Surgeon General, AMEDD Center & School, US Army, Washington D.C. M.K. Lenhart (Ed.).
106. Rest J.G., Goldstein E.J. Management of human and animal bite wounds. Emerg. Med. Clin. North. Am. 1985, 3:117-126.
107. Roffey R., Lantorp K., Tegnell A., Elgh F. Biological weapons and bioterrorism preparedness: importance of public-health awareness and international cooperation. Clin. Microbiol. Infect. 2002, 8:522-528.
108. Roffey R., Tegnell A., Elgh F. Biological warfare in a historical perspective. Clin. Microbiol. Infect. 2002, 8:450-454.
109. Rollins S.E., Rollins S.M., Ryan E.T. Yersinia pestis and the plague. Am. J. Clin. Pathol. 2003, 119(Suppl.):S78-S85.
110. Rusnak J.M., Smith L.A. Botulinum neurotoxin vaccines: past history and recent developments. Hum. Vaccin 2009, 5:794-805.
111. Schep L.J., Temple W.A., Butt G.A., Beasley M.D. Ricin as a weapon of mass terror-separating fact from fiction. Environ. Int. 2009, 35:1267-1271.
112. Schivao G., matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80:717-766.
113. Sejvar J.J., Tenover F.C., Stephens D.S. Management of anthrax meningitis. Lancet Infect. Dis. 2005, 5:287-295.
114. Selvaggi K., Saria E.A., Schwartz R., Vlock D.R., Ackerman S., Wedel N., Kirkwood J.M., Jones H., Ernstoff M.S. Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma. J. Immunother. Emphasis Tumor Immunol. 1993, 13:201-207.
115. Shafazand S., Doyle R., Ruoss S., Weinacker A., Raffin T.A. Inhalational anthrax: epidemiology, diagnosis, and management. Chest 1999, 116:1369-1376.
116. Shukla H.D., Sharma S.K. Clostridium botulinum: a bug with beauty and weapon. Crit. Rev. Microbiol. 2005, 31:11-18.
117. Smith L.A. Botulism and vaccines for its prevention. Vaccine 2009, 27(Suppl. 4):D33-D39.
118. Stark A.A. Threat assessment of mycotoxins as weapons: molecular mechanisms of acute toxicity. J. Food Prot. 2005, 68:1285-1293.
119. SteelFisher G., Blendon R., Ross L.J., Collins B.C., Ben-Porath E.N., Bekheit M.M., Mailhot J.R. Public response to an anthrax attack: reactions to mass prophylaxis in a scenario involving inhalation anthrax from an unidentified source. Biosecur. Bioterror. 2011, 9:239-250.
120. Stenseth N.C., Atshabar B.B., Begon M., Belmain S.R., Bertherat E., Carniel E., Gage K.L., Leirs H., Rahalison L. Plague: past, present, and future. PLoS Med. 2008, 5:e3.
121. Stern E.J., Uhde K.B., Shadomy S.V., Messonnier N. Conference report on public health and clinical guidelines for anthrax. Emerg. Infect. Dis. 2008, 14.
122. Storey S., Dangman K.D., Schenck P., DeBernardo R.L., Yang C.S., CIH A.B., Hodgson M.J. Guidance for Clinicians on the Recognition and Management of Health Effects Related to Mold Exposure and Moisture Indoors 2004, University of Connecticut Health Center, Farmington.
123. Switala C.A., Coren J., Filipetto F.A., Gaughan J.P., Ciervo C.A. Bioterrorism-a health emergency: do physicians believe there is a threat and are they prepared for it?. Am. J. Disaster Med. 2011, 6:143-152.
124. Tang J., Yu T., Guo L., Xie J., Shao N., He Z. In vitro selection of DNA aptamer against abrin toxin and aptamer-based abrin direct detection. Biosens. Bioelectron. 2007, 22:2456-2463.
125. Targosz D., Winnik L., Szkolnicka B. Suicidal poisoning with castor bean (Ricinus communis) extract injected subcutaneously - case report. J. Toxicol. Clin. Toxicol. 2002, 40:398.
126. Tissot-Dupont H., Raoult D. Q fever. Infect. Dis. Clin. North. Am. 2008, 22. 505-514, ix.
127. Titball R.W. Clostridium perfringens vaccines. Vaccine 2009, 27(Suppl. 4):D44-D47.
128. Tournier J.-N., Rossi Paccani S., Quesnel-Hellmann A., Baldari C.T. Anthrax toxins: a weapon to systematically dismantle the host immune defenses. Mol. Aspects Med. 2009, 30:456-466.
129. Tutelyan V.A., Kravchenko L.V., Kuzmina E.E., Avrenieva L.I., Kumpulainen J.T. Dietary selenium protects against acute toxicity of T-2 toxin in rats. Food Addit Contam. 1990, 7:821-827.
130. Ulrich R.G., Wilhelmsen C.L., Krakauer T. chapter 14, Staphlococcal enterotoxin B and related toxins. Medical Aspects of Biological Warfare 2008, 311-322. Borden Institute, Office of the Surgeon General, AMEDD Center & School, US Army, Washington D.C. M.K. Lenhart (Ed.).
131. Valerio E., Chaves S., Tenreiro R. Diversity and impact of prokaryotic toxins on aquatic environments: a review. Toxins (Basel) 2010, 2:2359-2410.
132. Vitetta E.S., Smallshaw J.E., Coleman E., Jafri H., Foster C., Munford R., Schindler J. A pilot clinical trial of a recombinant ricin vaccine in normal humans. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:2268-2273.
133. Voss J.E., Scally S.W., Taylor N.L., Atkinson S.C., Griffin M.D., Hutton C.A., Parker M.W., Alderton M.R., Gerrard J.A., Dobson R.C., Dogovski C., Perugini M.A. Substrate-mediated stabilization of a tetrameric drug target reveals Achilles heel in anthrax. J. Biol. Chem. 2010, 285:5188-5195.
134. Wannemacher R.W., Winenr S.L. Chapter 34 trichothecene mycotoxins. Textbook of Military Medicine. Part I. Warfare, Weaponry, and the Casualty. Medical Aspects of Chemical and Biological Warfare 1997, 655-676. Borden Institute, Walter Reed Medical Center, Washington, DC. R. Zajtchuk, R.F. Bellamy, F.R. Sidell (Eds.).
135. Waterer G.W., Robertson H. Bioterrorism for the respiratory physician. Respirology 2009, 14:5-11.
136. Whitby M., Street A.C., Ruff T.A., Fenner F. Biological agents as weapons 1: smallpox and botulism. Med. J. Aust. 2002, 176:431-433.
137. White J., Herman A., Pullen A.M., Kubo R., Kappler J.W., Marrack P. The V beta-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice. Cell 1989, 56:27-35.
138. WHO Botulism 2002, WHO.
139. Wiener S.L. Strategies for the prevention of a successful biological warfare aerosol attack. Mil. Med. 1996, 161:251-256.
140. Worbs S., Kohler K., Pauly D., Avondet M.A., Schaer M., Dorner M.B., Dorner B.G. Ricinus communis intoxications in human and veterinary medicine-a summary of real cases. Toxins (Basel) 2011, 3:1332-1372.